Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Edgewise Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights"
07/14/2023 8-K Quarterly results
06/28/2023 SC 13D/A Novo Holdings A/S reports a 9.6% stake in Edgewise Therapeutics, Inc.
06/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Common stock SALES AGREEMENT",
"Re: Registration Statement on Form S-3"
06/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights"
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors"
02/23/2023 8-K Quarterly results
Docs: "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights"
02/14/2023 SC 13G/A Cormorant Global Healthcare Master Fund, LP reports a 4.7% stake in Edgewise Therapeutics, Inc.
02/14/2023 SC 13G/A VIKING GLOBAL INVESTORS LP reports a 7% stake in Edgewise Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Flynn James E reports a 6.2% stake in Edgewise Therapeutics, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 13.6% stake in EDGEWISE THERAPEUTICS INC
02/01/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/11/2022 SC 13G/A FMR LLC reports a 12.6% stake in EDGEWISE THERAPEUTICS INC
09/30/2022 SC 13D/A Novo Holdings A/S reports a 9.6% stake in Edgewise Therapeutics, Inc.
09/26/2022 SC 13G EcoR1 Capital, LLC reports a 5.5% stake in Edgewise Therapeutics, Inc.
09/23/2022 SC 13G Deep Track Capital, LP reports a 5.3% stake in Edgewise Therapeutics, Inc.
09/16/2022 SC 13D/A ORBIMED ADVISORS LLC reports a 23.3% stake in Edgewise Therapeutics, Inc.
09/16/2022 SC 13D/A Novo Holdings A/S reports a 9.6% stake in Edgewise Therapeutics, Inc.
09/14/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"Follow-On Public Offering of Edgewise Therapeutics, Inc."
09/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/13/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investors & Media",
"Investors & Media",
"Updated Risk Factor Disclosure"
08/15/2022 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in EDGEWISE THERAPEUTICS, INC.
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
Docs: "Edgewise Therapeutics Reports Second Quarter 2022 Financial Results"
06/24/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy